MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/77.5/0.1/20.12.24 | Market Closed - Börse Stuttgart 19:39:51 28/06/2024 BST | ||
| 0.58 EUR | 0.00% |
|
| Current month | +1.69% | ||
| 1 month | +5.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.6 | +3.45% |
| 27/06/24 | 0.58 | -10.77% |
| 26/06/24 | 0.65 | -2.99% |
| 25/06/24 | 0.67 | +3.08% |
| 24/06/24 | 0.65 | +1.56% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 07:39 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB3F24 |
| ISIN | DE000MB3F247 |
| Date issued | 08/02/2023 |
| Strike | 77.5 $ |
| Maturity | 20/12/2024 (175 Days) |
| Parity | 10 : 1 |
| Emission price | 0.5 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.97 € |
|---|---|
| Lowest since issue | 0.068 € |
| Spread | 0.01 € |
| Spread % | 1.72% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.69%
- Stock Market
- Warrants
- Warrant
